Paper Details

  1. Home
  2. Paper Details

The Nucleoside Analog BMS-986001 Shows Greater In Vitro Activity against HIV-2 than against HIV-1.

Author: , BaSelly, GottliebGeoffrey S, LeongSally S, OakesMariah K, ParkerKate M, RaugiDana N, SeydiMoussa, SmithRobert A, SowPapa Salif, WuVincent H

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

BMS-986001, an investigational nucleoside analog, showed potent activity against HIV-2 replication in vitro, exhibiting greater efficacy against HIV-2 than HIV-1.
Paper Details　
Original Abstract of the Article :
Treatment options for individuals infected with human immunodeficiency virus type 2 (HIV-2) are restricted by the intrinsic resistance of the virus to nonnucleoside reverse transcriptase inhibitors (NNRTIs) and the reduced susceptibility of HIV-2 to several protease inhibitors (PIs) used in antiretr...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4649195/

データ提供：米国国立医学図書館（NLM）

BMS-986001: A Promising Nucleoside Analog for HIV-2 Treatment

The field of [HIV research] strives to develop effective treatments for [HIV-2 infection]. This study investigates the [in vitro activity] of the nucleoside analog [BMS-986001] against both [HIV-1] and [HIV-2]. The researchers, using [single-cycle assays], found that [key findings about the efficacy of BMS-986001 against HIV-1 and HIV-2].

BMS-986001: A Potent Inhibitor of HIV-2 Replication

This study demonstrates the potent [antiretroviral activity] of [BMS-986001] against [HIV-2], particularly its [superior efficacy compared to HIV-1]. The findings suggest that [BMS-986001] holds promise as a potential treatment option for [HIV-2 infection], a need considering the [challenges of treating HIV-2 infections].

A New Hope for HIV-2 Treatment

This study's findings offer a glimmer of hope for individuals living with [HIV-2 infection]. The discovery of [BMS-986001], a nucleoside analog with [strong efficacy against HIV-2], could lead to [potential benefits for HIV-2 patients]. Further research and clinical trials are needed to confirm the safety and efficacy of [BMS-986001] in treating [HIV-2 infection].

Dr.Camel's Conclusion

Like a camel traversing the vast desert of [HIV research], scientists are searching for effective treatments. This study presents a promising new weapon in the fight against [HIV-2]. With its potent antiviral activity and the potential to overcome the challenges of existing treatments, [BMS-986001] offers a new glimmer of hope for a healthier future for those living with [HIV-2 infection].

Date :
  1. Date Completed 2016-09-13
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26392486

DOI: Digital Object Identifier

PMC4649195

Related Literature

Article Analysis
・Effects of d4t
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.